Drug intelligence / Profile preview

XPose DDR small molecules

Development stage: Preclinical
Lead developer: Mid-Atlantic BioTherapeutics
Modality: Small Molecules

Overview

This program consists of DNA damage response (DDR) targeted small molecules developed by MidAtlantic BioTherapeutics (MABT) following its acquisition of XPose Therapeutics in February 2026. The research focuses on targeting 'undruggable' DDR proteins to treat various malignancies, including ovarian, breast, lung, and brain cancers. The program leverages XPose's expertise in structural biology and medicinal chemistry to address challenging targets within the DNA repair pathways, complementing MABT's existing immunotherapy and precision oncology platforms. The development is led by Dr. Debanu Das and Dr. Matthew Duncton.

Other names: XPose Therapeutics DDR programMidAtlantic BioTherapeutics DDR program

Beyond the preview

Go deeper on XPose DDR small molecules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XPose DDR small molecules.

Explore the full profile